Related Experiment Video
Updated: Jan 5, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Oral Anticoagulant Therapy-When Art Meets Science
Patricia Lorena Cîmpan1, Romeo Ioan Chira2,3, Mihaela Mocan4,5
1Department of Cardiology, Heart Institute, 40001 Cluj Napoca, Romania. pcimpan@gmail.com.
Insights
Vitamin K antagonists (VKA) are crucial for preventing thromboembolism, but dosing varies due to genetics. Genetic testing can guide VKA therapy and inform decisions about newer anticoagulants like NOACs.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Internal Medicine
Background:
- Anticoagulant therapy is vital for cardiovascular diseases, with Vitamin K antagonists (VKA) remaining essential despite newer options.
- VKA are recommended for specific conditions like prosthetic heart valves, rheumatic mitral stenosis, and certain thrombophilias, or when direct-acting oral anticoagulants (NOACs) are contraindicated.
- Significant inter-individual variability exists in VKA dosing, influenced by environmental factors and genetic determinants.
Purpose of the Study:
- To review genetic alterations affecting VKA metabolism and response.
- To highlight diagnostic options for patients with genetic variations impacting VKA therapy.
- To underscore the role of NOACs in managing rare and complex VKA-related issues.
Main Methods:
- Literature review of genetic factors influencing VKA therapy.
- Analysis of data on genetic alterations in diverse populations.
- Discussion of diagnostic strategies for VKA sensitivity/resistance.
Main Results:
- Approximately 30 genes, notably CYP2C9 and VKORC, are implicated in coumarin metabolism, with polymorphisms affecting VKA efficacy.
- Genetic variations can lead to increased sensitivity or resistance to VKA therapy, necessitating personalized dosing strategies.
- NOACs offer a valuable alternative for patients with genetic profiles complicating VKA management.
Conclusions:
- Genetic polymorphisms in genes like CYP2C9 and VKORC significantly impact VKA therapy, contributing to dosing variability.
- Identifying genetic alterations is crucial for optimizing VKA treatment and managing patients with higher sensitivity or resistance.
- NOACs provide a practical solution for complex cases where VKA therapy is challenging due to genetic factors.
Abstract:
Anticoagulant treatment is extremely important and frequently encountered in the therapy of various cardiovascular diseases. Vitamin K antagonists (VKA) are in use for the prevention and treatment of arterial and venous thromboembolism, despite the introduction of new direct-acting oral anticoagulants (NOAC). The VKA still have the clear recommendation in patients with a mechanical prosthetic heart valve replacement or moderate to severe mitral stenosis of the rheumatic origin, in deep vein thrombosis associated with congenital thrombophilia, and in cases where NOAC are prohibited by social condition (financial reason) or by comorbidities (extreme weight, severe renal or liver disease). VKA dosing required to reach the targeted therapeutic range varies largely between patients (inter-individual variability). This inter-individual variability depends on multiple environmental factors such as age, mass, diet, etc. but it is also influenced by genetic determinism. About 30 genes implicated in the metabolism coumarins derivatives were identified, the most important being CYP2C9 and VKORC, each with several polymorphisms. Herein, we review the data regarding genetic alterations in general and specific populations, highlight the diagnosis options in particular cases presenting with genetic alteration causing higher sensitivity and/or resistance to VKA therapy and underline the utility of NOAC in solving such rare and difficult problems.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care